win-51708 has been researched along with Cocaine-Related-Disorders* in 1 studies
1 other study(ies) available for win-51708 and Cocaine-Related-Disorders
| Article | Year |
|---|---|
The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine.
We tested the tachykinin NK(1) receptor antagonist WIN51708 (17betahydroxy17alphaethynyl5alphaandrostanol[3,2b]pyrimido[1,2-a]benzimidazole) in a behavioral sensitization model. Rats were given 7 days of cocaine then 7 days of withdrawal to induce sensitization. Thereafter, another 7 days of cocaine with WIN51708 (2 mg/kg i.p.) given 3.5 h after each cocaine injection was given. WIN51708 reversed sensitization but had no effect on controls. NK(1) receptor antagonists may have use in stimulant abuse and schizophrenia treatment. Topics: Androstanes; Animals; Behavior, Addictive; Behavior, Animal; Benzimidazoles; Cocaine; Cocaine-Related Disorders; Male; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Time Factors | 2004 |